Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Dementia remains one of the most pressing public health challenges of our time. Its economic burden exceeds $1 trillion ...

But the 72-year-old Mendoza, who has not been diagnosed with Alzheimer’s, isn’t getting the exam at a doctor’s office or a clinical lab. She’s in a comfortable and familiar place, sipping Cuban coffee ...

Retro Biosciences will back clinical trials for three drugs—including a potential Alzheimer’s disease treatment set to begin ...

We now have two FDA-approved disease-modifying treatments for Alzheimer's disease, and hundreds of clinical trials are ...

The disease afflicts nearly seven million Americans, about one in every nine people over the age of 65, making it a leading ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

The number of people living with neurological disorders, such as Alzheimer’s disease, epilepsy, multiple sclerosis and Parkinson’s disease, has increased as the population has aged. At the same time, ...

Lecanemab reduces toxic amyloid-β protofibrils, slowing Alzheimer’s disease progression and supporting personalised treatment ...

LATE is a prevalent condition in late life and can contribute to memory loss and cognitive decline, according to report ...

Vigil posted positive phase 1 results for VG-3927, but competitor Alector's failure raises concerns about phase 2. Click here ...

Early research suggests GLP-1 drugs could prevent or treat Alzheimer's Disease. Results from a big clinical trial could soon ...